Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children18910.24287/1726-1708-2018-17-3-36-42ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИTen years of experience of alendronate treatment of craniomaxillofacial fibrous dysplasia10-летний опыт лечения фиброзной дисплазии челюстно-лицевой области препаратами алендроновой кислотыhttps://orcid.org/0000-0002-6881-7709KugushevA. Yu.КугушевА. Ю.
Russian Federation

Alexander Yu. Kugushev, PhD, plastic surgeon, pediatric surgeon, Department of Maxillofacial Surgery

119571, Moscow, Leninsky рrosp., 117

Кугушев Александр Юрьевич, канд. мед. наук, врач пластический хирург, детский хирург, отделение челюстно-лицевой хирургии  

119571, Москва, Ленинский прос., 117

drkugushev@gmail.comhttps://orcid.org/0000-0003-0043-9059LopatinA. V.ЛопатинА. В.
Russian Federation
https://orcid.org/0000-0003-0319-3103YasonovS. A.ЯсоновС. А.
Russian Federation
Russian Childrens’ Clinical Hospital, Russian National Research Medical University named after N.I. PirogovРоссийская детская клиническая больница ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииPeoples' Friendship University of RussiaФГАОУ ВО «Российский университет дружбы народов»Russian National Research Medical University named after N.I. PirogovРоссийская детская клиническая больница ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России2409201817336422309201823092018Copyright ©; 2018, «D. Rogachev NMRCPHOI»Copyright ©; 2018, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2018«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/189

Fibrous dysplasia is a benign rare hamartom disease of bones, characterized by a combination of fibrous tissue elements in the focis. At the present time surgical treatment is the most preferable, however, in the case of small foci or subtotal skull bone affected this approach is not rational or impossible. The accumulated foreign and our experience of conservative treatment of patients with bisphosphonate series increases the possibilities for choosing the tactics of treating patients with this congenital pathology. When using this drug, there was no development of serious adverse effects and in a number of cases, surgical treatment was avoided.

Фиброзная дисплазия (ФД) – редкое доброкачественное гамартомное заболевание костей, характеризующееся соединением фиброзных костных элементов в очаге. В связи с отсутствием общепринятого универсального подхода к лечению ФД хирургическое лечение остается предпочтительным, однако в случае малых очагов или субтотального поражения костей хирургический метод нерационален или невозможен. Накопленный зарубежный и наш собственный опыт консервативного лечения пациентов препаратами бисфосфонатного ряда расширяет возможности выбора тактики лечения пациентов с данной врожденной патологией. При использовании бисфосфонатных препаратов не отмечено развития серьезных побочных реакций, а в ряде случаев удалось избежать оперативного лечения.

fibrous dysplasiabisphosphonateschildrenфиброзная дисплазиябисфосфонатыдети1. Assaf A.T., Benecke A.W., Riecke B., Zustin J., Fuhrmann A.W., Heiland M., et al. Craniofacial fibrous dysplasia (CFD) of the maxilla in an 11-year old boy: A case report. J Craniomaxillofac Surg 2012; 40: 788–92.Assaf A.T., Benecke A.W., Riecke B., Zustin J., Fuhrmann A.W., Heiland M., et al. Craniofacial fibrous dysplasia (CFD) of the maxilla in an 11-year old boy: A case report. J Craniomaxillofac Surg 2012; 40: 788–92.2. Волков М.В. Фиброзная остеодисплазия. – М., 1973.Волков М.В. Фиброзная остеодисплазия. – М., 1973.3. Feller L., Wood N.H., Khammissa R.A., Lemmer J., Raubenheimer E.J. The nature of fibrous dysplasia. Head Face Med 2009; 5: 22–7.Feller L., Wood N.H., Khammissa R.A., Lemmer J., Raubenheimer E.J. The nature of fibrous dysplasia. Head Face Med 2009; 5: 22–7.4. Tabrizi R., Ozkan B.T. Craniofacial fibrous dysplasia of orbit. J Craniofac Surg 2008; 19: 1532–7.Tabrizi R., Ozkan B.T. Craniofacial fibrous dysplasia of orbit. J Craniofac Surg 2008; 19: 1532–7.5. Keskin M., Karabekmez F.E., Ozkan B.T., Tosun Z., Avunduk M.C., Savaci N. Simultaneous occurrence of facial fibrous dysplasia and ameloblastoma. J Craniomaxillofac Surg 2009; 37: 102–5.Keskin M., Karabekmez F.E., Ozkan B.T., Tosun Z., Avunduk M.C., Savaci N. Simultaneous occurrence of facial fibrous dysplasia and ameloblastoma. J Craniomaxillofac Surg 2009; 37: 102–5.6. Nadaf A., Radhika M., Paremala K., Srinath N. Monostostic fibrous dysplasia with nonspecific cystic degeneration:A case report and review of literature. J Oral Maxillofac Pathol 2013 May; 17 (2): 274–80.Nadaf A., Radhika M., Paremala K., Srinath N. Monostostic fibrous dysplasia with nonspecific cystic degeneration:A case report and review of literature. J Oral Maxillofac Pathol 2013 May; 17 (2): 274–80.7. Valentini V., Cassoni A., Marianetti T.M., Terenzi V., Fadda M.T., Iannetti G. Craniomaxillofacial fibrous dysplasia: Conservative treatment or radical surgery? A retrospective study on 68 patients. Plast Reconstr Surg 2009; 123: 653–60.Valentini V., Cassoni A., Marianetti T.M., Terenzi V., Fadda M.T., Iannetti G. Craniomaxillofacial fibrous dysplasia: Conservative treatment or radical surgery? A retrospective study on 68 patients. Plast Reconstr Surg 2009; 123: 653–60.8. Kim D.D., Ghali G.E., Wright J.M., Edwards S.P. Surgical treatment of giant fibrous dysplasia of the mandible with concomitant craniofacial involvement. J Oral Maxillofac Surg 2012; 70:102–18.Kim D.D., Ghali G.E., Wright J.M., Edwards S.P. Surgical treatment of giant fibrous dysplasia of the mandible with concomitant craniofacial involvement. J Oral Maxillofac Surg 2012; 70:102–18.9. Delozier J.B., Egger M.E., Bottomy M.B. Infantile fibrous dysplasia of the mandible. J Craniofac Surg 2004 Nov; 15 (6): 1039–43.Delozier J.B., Egger M.E., Bottomy M.B. Infantile fibrous dysplasia of the mandible. J Craniofac Surg 2004 Nov; 15 (6): 1039–43.10. Eversole L.R., Sabes W.R., Rovin S. Fibrous dysplasia: A nosologic problem in the diagnosis of fibro osseous lesions of the jaws. J Oral Pathol 1972; 1: 189.Eversole L.R., Sabes W.R., Rovin S. Fibrous dysplasia: A nosologic problem in the diagnosis of fibro osseous lesions of the jaws. J Oral Pathol 1972; 1: 189.11. Kabukcuoglu F., Kabukcuoglu Y. Mazabraud's syndrome: Intramuscular myxoma associated with fibrous dysplasia. Orphanet Encyclopedia. 2005. [Last accessed on 2010 Dec 21]; pp. 1–4. Available from: https://www.orpha.net/data/patho/GB/uk-Mazabraud.pdfKabukcuoglu F., Kabukcuoglu Y. Mazabraud's syndrome: Intramuscular myxoma associated with fibrous dysplasia. Orphanet Encyclopedia. 2005. [Last accessed on 2010 Dec 21]; pp. 1–4. Available from: https://www.orpha.net/data/patho/GB/uk-Mazabraud.pdf12. Charpurlat R.D., Meunier P.J. Fibrous dysplasia of bone. Bailliere's Clin Rheumatol 2000; 14: 385–98.Charpurlat R.D., Meunier P.J. Fibrous dysplasia of bone. Bailliere's Clin Rheumatol 2000; 14: 385–98.13. Lala R., Matarazzo P., Andreo M., Defilippi C., de Sanctis C. Impact of endocrine hyperfunction and phosphate wasting on bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15 (Suppl 3): 913–20.Lala R., Matarazzo P., Andreo M., Defilippi C., de Sanctis C. Impact of endocrine hyperfunction and phosphate wasting on bone in McCune-Albright syndrome. J Pediatr Endocrinol Metab 2002; 15 (Suppl 3): 913–20.14. Boyce A.M., Chong W.H., Yao J., Kelly M.H., Chamberlain C.E., Bassim C., et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012;in press.Boyce A.M., Chong W.H., Yao J., Kelly M.H., Chamberlain C.E., Bassim C., et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012;in press.15. Park B.Y., Cheon Y.W., Kim Y.O., Pae N.S., Lee W.J. Prognosis for craniofacial fibrous dysplasia after incomplete resection: AGE and serum alkaline phosphatise. Int J Oral Maxillofac Surg 2010; 39: 221–6.Park B.Y., Cheon Y.W., Kim Y.O., Pae N.S., Lee W.J. Prognosis for craniofacial fibrous dysplasia after incomplete resection: AGE and serum alkaline phosphatise. Int J Oral Maxillofac Surg 2010; 39: 221–6.16. Chapurlat R.D., Hugueny P., Delmas P.D., Meunier P.J. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35 (1): 235–42.Chapurlat R.D., Hugueny P., Delmas P.D., Meunier P.J. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004; 35 (1): 235–42.17. Bachrach L.K., Ward L.M. Clinical review: bisphosphonate use in childhood osteoporosis. Journal of Clinical Endocrinology and Metabolism 2009; 94 (2): 400–9.Bachrach L.K., Ward L.M. Clinical review: bisphosphonate use in childhood osteoporosis. Journal of Clinical Endocrinology and Metabolism 2009; 94 (2): 400–9.18. Kitagawa Y., Tamai K., Ito H. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. Journal of Orthopaedic Science 2004; 9 (5): 521–5.Kitagawa Y., Tamai K., Ito H. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. Journal of Orthopaedic Science 2004; 9 (5): 521–5.19. Ana Luiza A.A., Ivani N.S. Oral alendronate treatment for severe polyostotic fibrous dysplasia due to McCune-Albright syndrome in a child: A case report International Journal of Pediatric Endocrinology 2010; Аrticle ID 432060: 1–4.Ana Luiza A.A., Ivani N.S. Oral alendronate treatment for severe polyostotic fibrous dysplasia due to McCune-Albright syndrome in a child: A case report International Journal of Pediatric Endocrinology 2010; Аrticle ID 432060: 1–4.20. Diaz A., Danon M., Crawford J. McCune-Albright syndrome and disorders due to activating mutations of GNAS1. Journal of Pediatric Endocrinology and Metabolism 2007: 20 (8): 853–80.Diaz A., Danon M., Crawford J. McCune-Albright syndrome and disorders due to activating mutations of GNAS1. Journal of Pediatric Endocrinology and Metabolism 2007: 20 (8): 853–80.21. Thomsen M.D., Rejnmark L.Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif Tissue Int 2014 Apr; 94 (4): 384–95.Thomsen M.D., Rejnmark L.Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia. Calcif Tissue Int 2014 Apr; 94 (4): 384–95.22. Ngan K.K., Bowe J., Goodger N. The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review. Dent Update 2013 Nov; 40 (9): 733–4, 736–8.Ngan K.K., Bowe J., Goodger N. The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review. Dent Update 2013 Nov; 40 (9): 733–4, 736–8.23. Lietman S.A., Schwindinger W.F., Levine M.A. Genetic and molecular aspects of McCune-Albright syndrome. Pediatr Endocrinol Rev 2007; 4 (suppl 4): 380–5.Lietman S.A., Schwindinger W.F., Levine M.A. Genetic and molecular aspects of McCune-Albright syndrome. Pediatr Endocrinol Rev 2007; 4 (suppl 4): 380–5.24. Lv M., Li X., Huang Y., Wang N., Zhu X., Sun J. Inhibition of fibrous dysplasia via blocking Gs with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system. Biomater Sci 2016 Jul 21; 4 (7): 1113–22.Lv M., Li X., Huang Y., Wang N., Zhu X., Sun J. Inhibition of fibrous dysplasia via blocking Gs with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system. Biomater Sci 2016 Jul 21; 4 (7): 1113–22.